This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khorana, A. A. Articles by Taubman, M. B. Search for Related Content PubMed PubMed Citation Articles by Khorana, A. A. Articles by Taubman, M. B.

Tissue Factor Expression, Angiogenesis, and Thrombosis in Pancreatic Cancer

Authors' Affiliations: ¹ James P. Wilmot Cancer Center, Department of Medicine; Departments of ² Pathology and Laboratory Medicine, ³ Surgery, and ⁴ Medicine, University of Rochester, Rochester, New York; ⁵ Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; ⁶ Departments of Pathology and Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland; and ⁷ Translational Genomics Research Institute, Phoenix, Arizona

Requests for reprints: Alok A. Khorana, James P. Wilmot Cancer Center, Department of Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 704, Rochester, NY 14642. Phone: 585-275-4797; Fax: 585-273-1042; E-mail: alok_khorana{at}URMC.rochester.edu.

Purpose: Hemostatic activation is common in pancreatic cancer and may be linked to angiogenesis and venous thromboembolism. We investigated expression of tissue factor (TF), the prime initiator of coagulation, in noninvasive and invasive pancreatic neoplasia. We correlated TF expression with vascular endothelial growth factor (VEGF) expression, microvessel density, and venous thromboembolism in resected pancreatic cancer.

Experimental Design: Tissue cores from a tri-institutional retrospective series of patients were used to build tissue microarrays. TF expression was graded semiquantitatively using immunohistochemistry in normal pancreas (n = 10), intraductal papillary mucinous neoplasms (n = 70), pancreatic intraepithelial neoplasia (n = 40), and resected or metastatic pancreatic adenocarcinomas (n = 130).

Results: TF expression was observed in a majority of noninvasive and invasive pancreatic neoplasia, including 77% of pancreatic intraepithelial neoplasias, 91% of intraductal papillary mucinous neoplasms, and 89% of pancreatic cancers, but not in normal pancreas. Sixty-six of 122 resected pancreatic cancers (54%) were found to have high TF expression (defined as grade 2, the median score). Carcinomas with high TF expression were more likely to also express VEGF (80% versus 27% with low TF expression, P < 0.0001) and had a higher median MVD (8 versus 5 per tissue core with low TF expression, P = 0.01). Pancreatic cancer patients with high TF expression had a venous thromboembolism rate of 26.3% compared with 4.5% in patients with low TF expression (P = 0.04).

Conclusions: TF expression occurs early in pancreatic neoplastic transformation and is associated with VEGF expression, increased microvessel density, and possibly clinical venous thromboembolism in pancreatic cancer. Prospective studies evaluating the role of TF in pancreatic cancer outcomes are warranted.

This article has been cited by other articles:

				A. A. Khorana, N. M. Kuderer, E. Culakova, G. H. Lyman, and C. W. Francis Development and validation of a predictive model for chemotherapy-associated thrombosis Blood, May 15, 2008; 111(10): 4902 - 4907. [Abstract] [Full Text] [PDF]

				A. A. Khorana, H. A. Liebman, R. H. White, T. Wun, and G. H. Lyman The Risk of Venous Thromboembolism in Patients with Cancer ASCO Educational Book, January 1, 2008; 2008(1): 240 - 248. [Abstract] [Full Text] [PDF]